0001140361-16-047842.txt : 20160114
0001140361-16-047842.hdr.sgml : 20160114
20160114174641
ACCESSION NUMBER: 0001140361-16-047842
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160112
FILED AS OF DATE: 20160114
DATE AS OF CHANGE: 20160114
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9143477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sanofi
CENTRAL INDEX KEY: 0001121404
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: I0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 161343710
BUSINESS ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
BUSINESS PHONE: 33153774400
MAIL ADDRESS:
STREET 1: 54 RUE LA BOETIE
CITY: PARIS
STATE: I0
ZIP: 75008
FORMER NAME:
FORMER CONFORMED NAME: SANOFI-AVENTIS
DATE OF NAME CHANGE: 20040826
FORMER NAME:
FORMER CONFORMED NAME: SANOFI SYNTHELABO SA
DATE OF NAME CHANGE: 20010104
4
1
doc1.xml
FORM 4
X0306
4
2016-01-12
0
0000872589
REGENERON PHARMACEUTICALS INC
REGN
0001121404
Sanofi
54, RUE LA BOETIE
PARIS
I0
75008
FRANCE
0
0
1
0
Common Stock
2016-01-12
4
P
0
5007
453.8912
A
23113577
I
See note
Common Stock
2016-01-12
4
P
0
2407
454.5971
A
23115984
I
See note
Common Stock
2016-01-12
4
P
0
2164
455.6774
A
23118148
I
See note
Common Stock
2016-01-12
4
P
0
3220
457.1844
A
23121368
I
See note
Common Stock
2016-01-12
4
P
0
3100
457.9952
A
23124468
I
See note
Common Stock
2016-01-12
4
P
0
2500
460.1156
A
23126968
I
See note
Common Stock
2016-01-12
4
P
0
3563
461.4128
A
23130531
I
See note
Common Stock
2016-01-12
4
P
0
4941
462.2263
A
23135472
I
See note
Common Stock
2016-01-12
4
P
0
2759
463.1723
A
23138231
I
See note
Common Stock
2016-01-12
4
P
0
4148
464.4110
A
23142379
I
See note
Common Stock
2016-01-12
4
P
0
8002
465.4998
A
23150381
I
See note
Common Stock
2016-01-12
4
P
0
3608
466.2618
A
23153989
I
See note
Common Stock
2016-01-12
4
P
0
4901
467.6617
A
23158890
I
See note
Common Stock
2016-01-12
4
P
0
5082
468.4646
A
23163972
I
See note
Common Stock
2016-01-12
4
P
0
14169
469.7058
A
23178141
I
See note
Common Stock
2016-01-12
4
P
0
7204
470.6444
A
23185345
I
See note
Common Stock
2016-01-12
4
P
0
3600
471.5617
A
23188945
I
See note
Common Stock
2016-01-12
4
P
0
3563
472.6410
A
23192508
I
See note
The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").
Purchase prices range from $453.09 to $454.07 per share, inclusive.
Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,392,956 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.
Purchase prices range from $454.21 to $455.19 per share, inclusive.
Purchase prices range from $455.24 to $456.19 per share, inclusive.
Purchase prices range from $456.59 to $457.54 per share, inclusive.
Purchase prices range from $457.60 to $458.41 per share, inclusive.
Purchase prices range from $459.64 to $460.52 per share, inclusive.
Purchase prices range from $460.71 to $461.66 per share, inclusive.
Purchase prices range from $461.73 to $462.71 per share, inclusive.
Purchase prices range from $462.83 to $463.46 per share, inclusive.
Purchase prices range from $463.96 to $464.92 per share, inclusive.
Purchase prices range from $464.99 to $465.93 per share, inclusive.
Purchase prices range from $465.99 to $466.97 per share, inclusive.
Purchase prices range from $466.99 to $467.94 per share, inclusive.
Purchase prices range from $468.09 to $468.87 per share, inclusive.
Purchase prices range from $469.11 to $470.10 per share, inclusive.
Purchase prices range from $470.11 to $471.10 per share, inclusive.
Purchase prices range from $471.14 to $471.92 per share, inclusive.
Purchase prices range from $472.31 to $473.23 per share, inclusive.
/s/ John Felitti, Associate Vice President, Corporate Law, Financial & Securities Law
2016-01-14